Nebraska Administrative Code
Topic - HEALTH AND HUMAN SERVICES SYSTEM
Title 180 - CONTROL OF RADIATION
Chapter 3 - LICENSING OF RADIOACTIVE MATERIAL
Section 180-3-006 - RADIOACTIVE DRUG: CAPSULES CONTAINING CARBON-14 UREA FOR "IN VIVO" DIAGNOSTIC USE FOR HUMANS

Current through September 17, 2024

This section addresses radioactive drugs containing carbon-14 urea for "in vivo" diagnostic use for humans.

006.01 EXEMPTIONS. Other than as provided in 180 NAC 3-006.02, any person is exempt from the requirements for a license set forth in the Act and from the regulations in 180 NAC 3 and 7 provided that such person receives, possesses, uses, transfers, owns or acquires capsules containing 37 kBq (1 µCi) Carbon-14 urea, allowing for nominal variation that may occur during the manufacturing process, each for "in vivo" diagnostic use for humans.

006.02 RESEARCH INVOLVING HUMAN SUBJECTS. Any person who desires to use the capsules for research involving human subjects must apply for and receive a specific license according to 180 NAC 7.

006.03 COMMERCIAL DISTRIBUTION. Any person who desires to manufacture, prepare, process, produce, package, repackage, or transfer for commercial distribution such capsules must apply for and receive a specific license from the U.S. Nuclear Regulatory Commission (NRC) according to 10 CFR 32.21.

006.04 ADDITIONAL REQUIREMENTS. Nothing in 180 NAC 3-006 relieves persons from complying with applicable U.S. Food and Drug Administration (FDA), other Federal, and State requirements governing receipt, administration, and use of drugs.

Disclaimer: These regulations may not be the most recent version. Nebraska may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.